Send us a Protocol

What Sponsors Should Look for in Centralized Monitoring

ICH E6(R3) is now in effect, and its requirements are well understood: sponsors define Critical-to-Quality (CtQ) factors at protocol design, set Quality Tolerance Limits (QTLs), and keep documented oversight throughout the study. Choosing a tool to do that is harder. The market runs from enterprise RBQM platforms to dashboard layers added on top of an existing EDC. 

TRI works with sponsors and CROs on oncology, rare disease and multi-site global programs. Most of them have already decided to adopt centralized monitoring. What they ask us is how to tell whether a given tool will work for the people who have to use it. 

Feature lists won’t answer that. The tool determines how your team spots risk, records its decisions and shows compliance to an inspector, and a poor choice is expensive to undo. Below are the criteria we suggest clinical operations and trial oversight leaders use, based on E6(R3), our implementation experience, and where industry adoption still falls short. 

Centralized monitoring needs its own evaluation criteria 

Under E6(R3), centralized monitoring is a formal part of trial oversight, with its own section in Annex 1 (3.11.4.2). Sponsors must run a risk-proportionate monitoring strategy, combining on-site, remote and centralized methods as the trial’s risks warrant, and keep documented traceability across all of it. 

Many products sold as centralized monitoring tools are analytics dashboards on top of existing data systems. They can show KRI thresholds and protocol deviation trends. Fewer support the rest of the workflow: defining CtQ factors, linking them to QTLs, tracking breach investigations, and producing the documentation E6(R3) expects for each quality deviation. 

Industry data shows the cost of that gap. The ACRO RBQM Working Group’s landscape survey covered nearly 5,000 trials across seven CROs. Risk assessment adoption was high, but adoption of individual RBQM components sat around 50% for new studies started in 2022. In its December 2024 publication, the group concluded that sponsors weren’t getting the expected benefit from risk assessments, largely because centralized monitoring and QTLs weren’t being implemented alongside them. 

Evaluating tools against the full workflow, rather than the risk assessment step alone, helps avoid repeating that pattern. 

Regulatory capabilities to expect out of the box 

Start with the governance structure E6(R3) sets out: CtQ factors at protocol design, pre-specified QTLs tied to those factors, site-level KRIs, and documented monitoring against all three. 

If a tool supports this natively, you won’t need custom integrations or manual workarounds to connect risk assessment to monitoring. Check whether the platform can: 

  • Define and maintain CtQ factors and link them to QTL thresholds in the same system 
  • Track site-level KRIs and alert automatically when a threshold is crossed 
  • Record QTL breach investigations, root cause analyses and resolutions in one auditable record 
  • Generate monitoring observations from configurable rules, so different teams apply them consistently 

 

TRI’s OPRA Central Monitoring is built around this structure. Its Study Hub brings KRIs and QTLs into one view, and rules-based automation creates and updates monitoring observations according to your workflows. Because risk assessment, risk management and centralized monitoring sit in one platform, traceability is recorded as the work happens. 

One test works well in vendor demos. Ask the vendor to follow a single CtQ factor from definition at study startup, through a QTL breach mid-study, to a documented resolution you can retrieve at closeout. If any step happens outside the platform, it wasn’t designed for E6(R3). 

Fit for your organization’s size 

E6(R3) applies equally to a global pharma company with a dedicated RBQM function and to a mid-size biotech running a single compound. Most centralized monitoring tools, however, were built for large pharma organizations with specialist RBQM teams, analytics support and the resources to configure complex systems. Smaller sponsors often have none of these. 

A June 2026 study in Therapeutic Innovation and Regulatory Science found that large pharmaceutical companies report using RBQM components on an average of 63% of active trials, compared with less than 48% for smaller companies. The authors attributed this gap partly to weaker operational readiness and limited change-management capacity. Both problems get worse when a tool demands more expertise and resource than the organization has. 

To judge whether a tool fits your organization, look at three areas. 

Deployment speed. How long from contract signature to live monitoring? If setup takes months of configuration, custom integrations and specialist consultants, a smaller sponsor will feel it in study timelines. 

Usability. At many mid-size sponsors, the CRA also leads clinical operations. Risk signals need to be presented so that person can act on them, without a separate analytics team to interpret them. 

Proportionality. E6(R3) calls for oversight proportionate to risk, and for some lower-complexity studies a well-documented manual process is enough. A good tool lets you scale its complexity to the study instead of putting every trial through a full enterprise configuration. 

We designed OPRA to work for sponsors of different sizes. Any team member can see how metrics change over time, find areas of concern and act on them without analytics training. Centralized monitoring depends on the people who receive risk signals being able to use the tool directly. 

Data integration 

Centralized monitoring draws on EDC, CTMS, lab data, safety databases and sometimes ePRO or eCOA. Most vendors claim integration. What matters is how they handle the data once it’s connected. 

Multi-vendor data. Sponsors working with several CROs often have several EDC and CTMS systems. A tool that integrates natively with only one vendor’s ecosystem leaves gaps in cross-site analysis. 

Data currency. Centralized monitoring is valuable because it finds problems early, while they can still be fixed. Weekly batch updates give up much of that advantage compared with near-real-time data. 

Analysis beyond display. Showing KRI thresholds across sites is useful. Applying statistical methods, including multivariate analysis, to find co-occurring anomalies and systemic patterns that single-metric thresholds miss is more useful still. 

OPRA’s dynamic filtering lets teams cut data by study, country, site, subject or endpoint to investigate anomalies, and its trend analysis shows how risks develop over time. Together they give a fuller view of study health than static threshold reports. 

The audit trail 

Vendor demos tend to focus on dashboards, which make a strong first impression. Inspectors focus on the decision record: why a monitoring approach was chosen, what evidence supported it, and how the strategy changed during the study. 

Many tools show current risk status clearly but don’t keep a complete, searchable record of what was done about each signal. Under E6(R3), sponsors must show that each identified risk was evaluated, and that each evaluation led either to documented action or to a documented reason for not acting. 

The trail should capture every monitoring observation, every action assigned and completed, every QTL breach investigation, and every change to the monitoring plan, each with a timestamp and rationale. At closeout you should be able to search and export all of it without rebuilding it from several systems. 

In OPRA, mitigations remain fully searchable after closeout. Each action has a named owner, is tracked to resolution and is stored in one central record, so inspection preparation means retrieving records that already exist rather than reconstructing them in the weeks before an audit. 

To test this, ask the vendor to show the full record for one risk signal from detection to closeout. Gaps in that record, or a need to pull for inspection readiness. m several systems, are a direct risk to  

The financial case 

The financial question goes beyond license fees. A June 2026 study in Therapeutic Innovation and Regulatory Science by the Tufts Center for the Study of Drug Development measured RBQM’s return across 18 oncology trials. RBQM-enabled trials had clinical phase durations 8–19% shorter, and monitoring costs fell by up to 18% under a 10% source data verification scenario. Total ROI ranged from $3.2 million in Phase 1 to $18.9 million in Phase 3, or 6x to 23x the investment. 

Time savings made up 75–97% of that value. Most of monitoring’s financial impact, in other words, comes from avoiding downstream delays rather than from reducing monitoring labour. 

So, the useful question for a buyer is whether a platform helps the team find risks sooner and act on them faster. A tool that raises alerts but has no action workflow, or relies on a separate issue management system, slows the response and erodes the time savings the Tufts study measured. 

Across more than 500 clinical trials, OPRA Central Monitoring has delivered efficiency gains of up to 30% by shortening review cycles and automating routine monitoring tasks, leaving teams more time for clinical decisions. 

Centralized monitoring tool or full RBQM platform? 

A centralized monitoring tool, in the narrow sense, provides dashboards, KRI tracking and statistical oversight of study data. A full RBQM platform connects risk assessment, risk management and centralized monitoring so that each step feeds the next. 

The difference shows at each stage of a study: 

  • Startup: teams build risk assessments from a standard risk library, categorize risks by phase, design or therapeutic area, and carry them straight into the monitoring plan. 
  • Conduct: signals from centralized monitoring link back to the original risk assessment, so you can see whether the risks you planned for are the ones that occurred. 
  • Closeout: the full chain from risk identification through mitigation and monitoring sits in one system. 

With a standalone monitoring tool, sponsors usually keep risk assessments elsewhere, often in spreadsheets or a separate quality management system, and reconcile them by hand. That adds work and creates the documentation gaps inspectors look for. 

OPRA has three modules, OPRA RAM (Risk Assessment and Management), OPRA Central Monitoring and OPRA Subject Monitoring. They can be used separately, but they’re designed to work together. That gives sponsors E6(R3) traceability without stitching it together from separate systems. 

Summary 

When evaluating centralized monitoring tools, focus on five things: 

  1. Alignment with the E6(R3) governance structure
  2. Fit for your organization’s size and resources 
  3. Data integration that supports genuine cross-site analysis 
  4. An audit trail that will stand up to inspection 
  5. A connected workflow from risk assessment through monitoring to closeout 

 

If you’d like to see how OPRA handles the full RBQM lifecycle, contact us to arrange a demo.